General Court finds no likelihood of confusion between pharma marks with same suffix; annuls Board of Appeal decision

European Union

The EU General Court has annulled a decision of the Board of Appeal of the EUIPO finding that there was a likelihood of confusion between Tillotts' XENASA mark and Ferring’s earlier PENTASA mark in Class 5.

Unlock unlimited access to all WTR content